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Synthesis, radiolabelling and in vitro imaging of multifunctional 
nanoceramics  
Marina Lledos,[a] Vincenzo Mirabello,[a]* Sophia Sarpaki,[a] Haobo Ge,[a] Hubert J. Smugowski,[a] 
Laurence Carroll,[b] Eric O. Aboagye,[b] Franklin I. Aigbirhio,[c] Stanley W. Botchway,[d] Jonathan R. 
Dilworth,[e] David G. Calatayud,[a,f] Pawel K. Plucinski,[g] Gareth J. Price[a]* and Sofia I. Pascu[a]* 
Abstract: Molecular imaging has become a powerful technique in 
preclinical, clinical research and the diagnosis of many diseases. In 
this work, we address for the first time the synthetic challenges in 
achieving lab-scale, batch-to-batch reproducible 64Cu and 68Ga 
radiolabelled MNPs for imaging purposes. Composite nanoparticles 
incorporating magnetic iron oxide cores with luminescent quantum 
dots were simultaneously encapsulated within a thin silica shell, 
yielding water-dispersible, biocompatible and luminescent NPs. Novel, 
scalable surface modification protocols to attach the radioisotopes 
64Cu (t1/2 = 12.7 h) and 
68Ga (t1/2 = 68 min) in high yields are reported 
which are compatible with the time frame of radiolabelling. Confocal 
and fluorescence lifetime imaging studies confirm the uptake of the 
encapsulated imaging agents and their cytoplasmic localization in 
prostate cancer (PC-3) cells. Cellular viability assays show that the 
biocompatibility of the system is improved when the fluorophores are 
encapsulated within a silica shell. The functional and biocompatible 
SiO2 matrix represents an ideal platform for the incorporation of 
64Cu 
and 68Ga radioisotopes with high radiolabelling incorporation. 
Introduction 
The self-assembly and subsequent surface functionalization of 
mesoporous silica nanoparticles enable the formation of new 
materials with highly controllable properties for theranostic 
nanomedicine.[1],[2] Molecular imaging plays a key role in 
personalized and targeted medicine.[3] Each type of in-vivo 
imaging technique has its own advantages and limitations such 
as spatial and/or temporal resolution, sensitivity, signal-to-noise 
ratio SNR, penetration depth in tissue, quantitative accuracy[4] 
and differentiating postsurgical residual disease and 
postchemotherapy/postradiation lesions.[5] It has been 
acknowledged that there is no single modality, available amongst 
current molecular imaging techniques, capable to acquire alone 
all of the essential information across length scales of molecules 
to tissues and organs. Positron emission tomography (PET) is 
very sensitive and highly quantitative but has a poor spatial 
resolution. Magnetic resonance imaging (MRI) has superior 
resolution compared to PET as well as good soft tissue contrast, 
but low sensitivity. Optical fluorescence imaging cannot 
accurately quantify in-vivo fluorescence signals in large (more 
than 10 mm) living subjects. Thus, a combination of techniques 
(‘multimodal imaging’) is an essential tool in imaging at the 
research stage and in translational studies to a clinical 
setting.[6],[7],[8],[9] Simultaneous PET-MR imaging is one 
example,[10] which shows promise for the next generation of dual-
modality medical imaging.[11] This requires reliable and batch-to-
batch reproducible synthetic methods for new classes of imaging 
probes.[12] Currently, the most studied dual-modal imaging agent 
is based on a PET isotope combined with gadolinium for MRI,[13] 
but longer-term concerns include the deposition of Gd from linear 
chelators.[14] Insoluble deposits of gadolinium phosphate have 
been found in many organs such as skin, liver, lungs, ileum, 
kidney, skeletal muscles and brain.[14b, 15] 
Recently developed dual-mode contrast agents are based 
on benign magnetic nanoparticles (MNPs) and are starting to be 
used in clinical trials for MRI.[16],[17],[18] Such MNPs have iron oxide 
cores that are superparamagnetic and so enable tracking of 
theranostic nanomedicines by MRI.[19],[20] Stoddart et al. created 
targeted a drug delivery system for the treatment of cancer and 
degenerative diseases.[21],[22] To date, examples of fully 
characterized dual-(multi)-mode imaging probes have been 
described for simultaneous PET/MRI or PET/MRI/NIRF (near 
infrared fluorescence).[23] The preparation of serum albumin 
modified MnFe2O4 nanoparticles conjugated with 124I has been 
reported.[7] Amino acid modified MNPs coupled to cyclic arginine-
glycine-aspartic (RGD) peptides for integrin αvβ3 targeting with 
macrocyclic 1,4,7,10-tetraazacyclododecane-N,N′,N″,N′″-
tetraacetic acid (DOTA) chelators labelled with 64Cu (t1/2 = 12.7 h) 
for PET were also described.[24] A route to radiolabelling of 
dextran sulphate-coated superparamagnetic iron oxide 
nanoparticles with 64Cu[25] was developed where the radioactive 
centres were coordinated to the chelating bifunctional ligand, S-
2-(4-isothiocyanatobenzyl)-1,4,7,10-tetraazacyclododecane-
1,4,7,10-tetraacetic acid (p-SCN-Bz- 
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Figure 1. Schematic representation of the magnetic nanocomposites studied in this work. 
 
DOTA), and subsequently conjugated to the surface of the MNPs. 
Devaraj et al. reported the synthesis and in vivo characterization 
of 18F modified tri-modal MNPs [26] consisting of a shell of cross-
linked dextran, around a core of iron oxide and functionalized with 
the radionuclide 18F in high yields via click chemistry. Iron oxide 
MNPs with a compact human serum albumin coating (HSA-
IONPS), dually labelled with [64Cu]Cu-DOTA and Cy 5.5, were 
synthesised[27] as a tri-modal imaging agent for PET/MRI/NIRF. 
The synthesis of a probe consisting of a superparamagnetic iron 
oxide (SPIO) core coated with PEGylated phospholipids has been 
reported.[11] PEG ends were conjugated to DOTA to allow 
labelling with 64Cu. PEG chains were also used together with 
bisphosphonate anchors to SPIO NPs with [99mTc] complexes, 
resulting in a multimodal in vivo imaging agent.[28] 
Bisphosphonate ligands were also designed to bridge 64Cu and 
SPIO NPs.[29] Green and Blower reported the synthesis, 
characterization of a series of CoxFe(3-x)O4@NaYF4 core-shell 
NPs doped with 18F, offering PET/SPECT, MR and up-conversion 
fluorescence imaging.[30] However, in most of these cases, 
complex chemical reactions are needed to radiolabel the MNPs 
or to anchor the fluorescent dyes. A potential problem is a 
possible solvolysis and/or MNP degradation that may occur over 
time in aqueous media and, to a higher extent, in a biological 
environment.[29] In order to extend the use of the new functional 
MNPs to the radiopharmaceuticals, these synthetic challenges at 
their assembly need to be urgently addressed. Encapsulation of 
a molecular imaging probe for functional imaging and/or 
therapeutic applications within a magnetic nanoparticle 
represents an excellent method for kinetic stabilization and 
successful delivery of the probe to the targeted tissue.[31] Coating 
MNPs with silica is a promising approach since it is readily 
derivatised and it also reduces non-target cytotoxicity. 
[11],[32],[33],[34],[35],[36],[37] Furthermore, the use of quantum dots (QDs) 
in live-cell imaging studies has been shown to be valuable due to 
both their capacity as luminescent agents capable of absorption 
across broad wavelengths but sharp emission bands and their 
superior resistance to photo-bleaching compared with most 
commercial dyes. [38],[39],[40],[41] However, it has been reported that, 
although core-shell QDs can be more robust than those with 
organic coatings, the thickness of the inorganic shell (ZnS) can 
degrade the optical properties of the core.[42] Their usefulness as 
imaging agents has also been hampered by controversies related 
to the potential toxicity of the shell materials. There is a need for 
encapsulation techniques using benign materials with retention of 
efficient emission in biological media and provision of highly 
kinetically stable species.[43],[44] Silica is an attractive alternative in 
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this regard since, as noted above, it is biocompatible and can be 
easily functionalized.[45]  
 This work aims to overcome the limitations of current 
systems to develop a novel series of MNPs for imaging purposes 
(Figure 1). Reproducible synthesis and characterization protocols 
of such MNPs incorporating imaging agents such as QDs 
(Cd0.1Zn0.9Se and CdSe/ZnS) or Zn(II)[ATSM]/A, 68Ga[ATSM]/A 
(ATSM/A = diacetyl-2-(4-N-methyl-3-thiosemicarbazonato)-3-(4-
N-amino-3-thiosemicarbazonato) and hypoxia tracers 
[64Cu]Cu(OAc)2 and 64Cu[ATSM]/A[46] are reported. 
The radioactive tracers [64Cu]Cu(OAc)2 and 64Cu[ATSM]/A 
display appreciable hypoxia selectivity versus normoxia, and can 
be used for the delineation of tumour cells deprived of oxygen,[47] 
as well as ischemic and hypoxic myocardium.[48] The metal 
complex was first used in clinical trials in 2000 as an imaging 
agent for tumor hypoxia.[49] Ga[ATSM]/A is a new system that this 
far did not show sufficient kinetic stability in the radiolabeled 
form.[50],[51],[52] We and others [31] have also designed and 
developed new methods to incorporate radioisotopes to chelator-
free nanoparticles, and characterised emerging nanomedicines in 
vitro and in vivo. New core-shell nanomaterials with high kinetic 
stability in aqueous media are reported hereby.  
New nanoceramics based on hybrid stystems denoted NPs 
and MNPs were generated via self-assembled techniques, using 
a novel microemulsion method while encapsulating a range of 
imaging agents, including: nano-materials-based species (QDs), 
model inorganic systems (Re(VII) oxo-species), radioactive 
complex ions (64Cu and 68Ga)  and radiotracer precursors 
(64Cu(Cu(ATSM) and also their Ga(III) analogues). Fluorophores 
were encapsulated within a silica shell to investigate the in vitro 
uptake in prostate cancer cells (PC-3), a non-cancerous fibroblast 
cell line (FEK-4) and Chinese hamster ovary (CHO). Multiphoton 
fluorescence spectroscopy and imaging techniques were used for 
the first time to describe the environmental changes in the nature 
of the fluorophor upon encapsulation in NPs/MNPs and upon 
internalisation in cells.The potential for simultaneous and versatile 
derivatisation of NPs and MNPs whilst retaining their kinetic 
stability in the aqueous and biological environment are probed 
extensively by a range of spectroscopic and imaging techniques 
and discussed hereby for the first time.  
Results and Discussion 
Incorporation of optical imaging agents into core-shell 
Fe3O4@SiO2 magnetic nanoparticles (MNPs) 
Optimising the efficacy of a (dark) contrast MRI agent has 
been one of the challenges that attracted the attention of many 
research groups.[53] Over the course of the years, nanotechnology 
offered solutions to generate contrast agents able to yield high 
R2/R1 or R2*/R1 ratios.[54] Very efficient routes to enhance 
R2/R2* values are provided by the synthesis and use of SPIO 
NPs.[55] To address the challenge, magnetic iron oxide 
nanoparticles were synthesised via a co-precipitation method and 
encapsulated with silica via a microemulsion coating method. 
Similar techniques have been used to synthesise uniformly sized  
Figure 2. TEM micrographs of a) Fe3O4, b) Fe3O4@SiO2 (A), c) 
Fe3O4@SiO2@Zn[ATSM]/A (D), and d) Fe3O4/Cd0.1Zn0.9Se@SiO2 (C). 
and high quality, silica coated MNPs using a water-in-oil (W/O) 
microemulsion method.[56],[57] The formation of magnetic, 
crystalline Fe3O4 nanoparticles was confirmed by powder X-ray 
diffraction (ICDD file no. 86–2368, see ESI). The presence of 
silica was confirmed by FTIR vibrations at around 1100 cm-1 (Si-
O symmetric stretch) and 820 cm-1 (asymmetric Si-O stretch)[58]. 
Magnetization curves obtained by SQUID (Superconducting 
Quantum Interference Device) showed the typical characteristics 
of superparamagnetic behavior, zero coercivity and no 
remanence on hysteresis, for the NPs samples. The 
magnetization (normalized per gram of sample) observed for 
Fe3O4@SiO2 (A) was one-third of that measured for pure Fe3O4 
MNPs. The core-shell structure of the MNPs was confirmed by 
TEM (Figure 2). These MNPs have consistent, almost spherical 
morphology and the particles are well dispersed with sizes in the 
range of 5-10 nm for the iron oxide cores and 50-60 nm when 
encapsulated by silica. To address the optical imaging modalities, 
initial attempts to incorporate optical imaging agents focused on 
encapsulation of fluorescent organic dyes such as methylene blue 
MB, fluorescein FL, rhodamine B, Ru(bpy) into the silica shell and 
comparing their fluorescence efficiencies with the same NPs 
containing two classes of QD fluorophores; Lumidot 480 and 
Cd0.1Zn0.9Se nanocrystals.  
Based on methods proposed by Wu et al.[64] and Jacinto et al.,[61] 
the fluorophores were incorporated using a one-step 
microemulsion method. TEM micrographs of such NPs are 
FULL PAPER    
 
 
 
 
 
Figure 3. Laser-scanning confocal microscopy (a-d) of CHO cells treated with 10 µg/mL Fe3O4/CdSe/ZnS@SiO2 (B) in water, incubated for 15 mins at 
37 °C and two-photon fluorescence lifetime imaging (e-g) of the same area. a) DIC image; b) green channel; c) red channel; d) overlay of the green-red 
channels; λex = 488 nm; e-f) two-photon fluorescence lifetime map; g) associated profile distribution. Colors provide a direct correlation between the 
lifetime maps and the lifetime histograms. Laser power: 2.0 mW at 910 nm wavelength. a-f) Scale bar: 20 µm; e and f show the same field of view. 
 
illustrated in Fig. S9-S13 (ESI). However, none of the 
nanoparticles prepared using organic fluorophores exhibited 
significant luminescence. A reverse microemulsion method was 
employed to encapsulate Lumidot 480 QDs, resulting in core-shell 
fluorescent Fe3O4/CdSe/ZnS@SiO2 (B) composite nanoparticles, 
the morphology of which can be seen by TEM (Figure S14). It is 
well known that QDs have higher extinction coefficients and 
quantum yields compared with organic dyes.[41],[59],[60]  
Two-photon laser scanning confocal microscopy was performed 
on Fe3O4/CdSe/ZnS@SiO2 (B) NPs in order to establish their 
potential as fluorescent imaging agents for in vitro cells and tissue 
studies. Chinese hamster ovary (CHO) cells were grown 
according to standard protocols, placed onto glass bottom dishes 
and allowed to grow to suitable confluence (see ESI for cell 
culture and plating details). Figure 3a-d shows bright field 
confocal images, the overlay of green-red channels and individual 
channel emissions (green: λem = 515-530 nm; red: λem =605-675 
nm). The images prove that, over a period of 15 minutes, the 
nanocomposite particles are taken up into cells and distributed 
across the cytoplasm with a large majority of emission lying in the 
green and red wavelength ranges. The fluorescence lifetime map 
distribution in CHO cells and the associated distribution profile of 
a water suspension of Fe3O4/CdSe/ZnS@SiO2 (B) are shown in 
Figure 3e-f and Figure 3g respectively. Fluorescence decays 
were fitted to two components. The major component (τ1, a1 = 
88.2 %) had a lifetime of 230 ps. A minor and longer second 
component (τ2 = 3216.5 ps, a2 = 11.8 %) was also detected. As 
previously reported, the presence of a second longer component 
may suggest the presence of NP aggregates in suspension.[61] 
However, the percentage of such secondary component, 
although significant, remains lower (11.8%) than that previously 
reported for nanocomposite materials (31.1%).[61] These studies 
suggest, therefore, that simultaneous encapsulation of QDs and 
magnetic Fe3O4 nanocrystals into a SiO2 shell produces a 
nanocomposite material capable of being internalized and 
producing a stable fluorescent environment within cells. The 
predominance of the major component, measured by time-
correlated single photon counting (TCSPC) is also observed 
when the NPs are suspended in DMSO (τ1 = 24 ps, a1 = 97.3 %; 
τ2 = 611.7 ps, a2 = 2.7 %). The major component, τ1, is likely 
derived mainly from the core of the iron oxide nanocrystals. The 
difference in lifetimes suggests that the intra-cellular environment 
may influence the aggregation of the fluorescent NPs within 
cellular compartments.[62] 
 
Encapsulation of cadmium quantum dots into MNPs 
Cadmium-containing quantum dots are known to be toxic, 
which is in large part attributed to the presence of free Cd2+ ions 
released when non-coated QDs are exposed to the acidic 
microenvironment after cellular uptake.[63] Soenen and 
collaborators[64] employed the degradation of Cadmium quantum 
dots to correlate the loss fluorescence intensity the number of 
cancer cells. Recent studies have shown that the toxicity of NPs 
can also be exploited as a novel means of providing cancer 
therapeutic effects. Pompa et al.[65] reported that ion-releasing 
FULL PAPER    
 
 
 
 
 
NPs may induce high levels of cytotoxicity due to the so-called 
lysosome-enhanced Trojan horse effect. Furthermore, recent 
studies have demonstrated that the surface coating of QDs can 
substantially influence the toxicity of the particles.[66] Particularly, 
Chu and collaborators demonstrated that the silica coating of 
CdSe QDs reduces the release of Cd ions by up to 99.45%.[67] 
We also report the synthesis of a less-common species of 
quantum dots, Cd0.1Zn0.9Se. Cd0.1Zn0.9Se nanocrystals were 
synthesized as reported by Knoll et al.[68] by doping CdSe with 
Zn(II) cations and Se(0) stabilized in solution via organic 
phosphines.[68],[69] Unlike the commercially available CdSe/ZnS 
QDs used above, in this QD system the Zn(II) and Se are not part 
of the protective shell of CdSe but are effective elements of the 
quantum dot core, capable of emitting simultaneously in the blue 
and red regions of the spectrum. Encapsulation of Fe3O4 and 
quantum dots with a silica shell to form Fe3O4/Cd0.1Zn0.9Se@SiO2 
(C) proceeded via a microemulsion method. While Ying et al. 
reported the synthesis of the first QD doped MNPs encapsulated 
within silica,[32] their method required 48 h for completion.  
Our method (see ESI) produces effective nanomaterials suitable 
for optical biosensing in a considerably shorter period of time (16 
h or less) which is fully adaptable to work under the confinements 
of a radiochemical laboratory. 
 Figure 2d shows a typical TEM micrograph of core-shell 
Fe3O4/Cd0.1Zn0.9Se@SiO2 (C) NPs, indicating dimensions around 
50-60 nm. Dynamic light scattering (DLS) showed that 
dispersions in chloroform Cd0.1Zn0.9Se and of Fe3O4, 
Fe3O4/Cd0.1Zn0.9Se@SiO2 (C) NPs in water had size distributions 
centered at 25, 45 and 300 nm respectively (Fig. S23, ESI). 
Although the DLS suggests a small amount of aggregation in 
solution, it is known that this technique yields higher diameters 
than those observed by TEM.[70],[71],[72] TEM and HRTEM 
demonstrate that the NPs have a core-shell structure with a dark 
contrast metal core and a light contrast silica shell. The successful 
incorporation of Fe3O4 and Cd0.1Zn0.9Se into silica shell NPs was 
confirmed by optical spectroscopy and the presence of Fe, Zn, Cd 
and Se peaks (Figure S17-S20) in energy-dispersive X-ray (EDX) 
spectra. The atomic percentage of Fe and Se were 5.98% and 
1.01%, respectively, which approximately corresponds to a 2:1 
Fe3O4:Cd0.1Zn0.9Se ratio. The FTIR spectrum and magnetization 
curves are shown in Fig. S22 (ESI). 
Both the freshly synthesized Cd0.1Zn0.9Se and the 
corresponding nanocomposites Fe3O4/Cd0.1Zn0.9Se@SiO2 (C) 
exhibit fluorescence emission assignable to these QDs. Figure 4 
shows the fluorescence spectrum of Cd0.1Zn0.9Se QDs recorded 
in dilute hexane dispersions (λex = 350 nm and λex = 252 nm) and 
Fe3O4/Cd0.1Zn0.9Se@SiO2 (C) in methanol dispersions. Free, non-
encapsulated QDs emit between 360 – 460 nm and 535 – 670 nm 
with λmax at 395 nm and 607 nm, respectively. The relative 
fluorescence quantum yield (QY) for Cd0.1Zn0.9Se was determined 
before and after silica encapsulation and estimated with respect 
to anthracene in cyclohexane as a standard. [73],[74] The quantum 
yield of freshly prepared Cd0.1Zn0.9Se QDs was 0.15 (λex = 350 
nm) and 0.14 (λex = 252 nm). It is interesting to note that Fe3O4 
and SiO2 present simultaneously act as passivating agents for the 
Cd0.1Zn0.9Se nanocrystals.[75],[76],[76],[11],[77] The fluorescence 
spectrum (λex = 252 nm) of silica-encapsulated Fe3O4/QDs shows  
Figure 4. Fluorescence spectra of Cd0.1Zn0.9Se (hexane: λex = 350 nm, red 
line; λex = 252 nm, blue line) Fe3O4/Cd0.1Zn0.9Se@SiO2 (C) (methanol: λex 
= 252 nm, black line). 
the characteristic emission peaks in the red (552 - 687 nm) and 
blue (277 - 368 nm) regions with λmax at 301 nm and 593 nm, 
respectively. UV-Visible spectra of the QDs before and after silica 
encapsulation are shown in Fig. S24 and S25 (ESI) respectively. 
The presence of Fe3O4 and the silica shell around Cd0.1Zn0.9Se 
decreased the QY. Indeed, for Fe3O4/Cd0.1Zn0.9Se@SiO2 (C) NPs 
the fluorescence was reduced by a factor of 100 (QY = 0.0014). 
Despite showing a significantly reduced fluorescence QY, the 
Fe3O4/Cd0.1Zn0.9Se@SiO2 (C) NPs retained a luminescence 
emission profile which was traceable in dried thin films by confocal 
fluorescence microscopy.  
Epi-fluorescence microscopy (Figure S50a-e) was used for 
PC-3 cells incubated with a DMSO : RPMI serum free medium (1 : 
99) suspension (10 µg/mL) of Fe3O4/Cd0.1Zn0.9Se@SiO2 (C) in 
order to establish the potential of such NPs as cancer cell imaging 
agents. PC-3 cells were grown according to standard serial  
passage protocols, plated onto glass bottom dishes and allowed 
to grow up to a suitable confluence (see ESI for cell culture and 
plating details).The Fe3O4/Cd0.1Zn0.9Se@SiO2 (C) NPs are up 
taken in PC-3 cells, with higher emission in the blue and green 
wavelengths with lower emission in the red wavelengths. Figure 
5 shows confocal microscopy imaging of PC-3 cells incubated for 
15 minutes with Fe3O4/Cd0.1Zn0.9Se@SiO2 (C) NPs. Again, most 
emission was seen in the blue and green regions. However, there 
is broad emission across the visible spectrum when the probe is 
exited at 405 nm, while only green-red emission is visible when 
excited with 488 or 561 nm lasers (Figure S47-S50). This is 
consistent with the fluorescence studies presented earlier where 
the Fe3O4/Cd0.1Zn0.9Se@SiO2 (C) NPs emitted blue and red 
wavelengths. The confocal microscopy images suggest that the 
Fe3O4/Cd0.1Zn0.9Se@SiO2 (C) NPs are located throughout the cell 
cytoplasm and no emission comes from the nuclear region of the 
cells. Therefore, we conclude that while the 
Fe3O4/Cd0.1Zn0.9Se@SiO2 (C) NPs are effectively internalised 
within the cell, they do not penetrate the nuclear membrane. 
 Cellular uptake of these nanocomposite particles was also 
conducted using a non-cancerous fibroblast cell line, FEK-4, (Fig.  
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Figure 5. a-e) Single-photon laser-scanning confocal microscopy of PC-3 
cells incubated for 15 minutes with Fe3O4/Cd0.1Zn0.9Se@SiO2 (C) NPs. 
Final concentration: 10 μg/mL in 1 : 99 DMSO : serum free medium at 
37 °C. a) DIC channel; b) blue channel (λem = 417-477 nm); c) green 
channel (λem = 500-550 nm); d); red channel (λem = 570-750 nm); e) 
overlapping of the DIC, blue, green and red channels. λex = 405.0 nm. 
Scale bar: a-e) 20 μm. 
S34-S38, ESI). No alteration in the morphology of the cells was 
apparent up to 6 hours after addition, a timescale far exceeding 
most common cellular imaging experiments in living cells.[78],[79] 
After 4 h incubation, a z-stacking experiment showed that the NPs 
are evenly distributed throughout the cytoplasm in addition to 
adhering to the outer cellular membrane. It is frequently assumed 
that adherence to the cell surface may be the beginning of uptake 
via endocytosis; in our hands, however, internalization was not 
observed within a standard time-point imaging experiment (e.g. 1 
h incubation at either 37 °C or 4 °C).  
The biocompatibility of mesoporous silica NPs has been 
extensively studied in the past. It is known that the toxicity of silica 
NPs is a concentration-dependent factor.[80] While silica NPs are 
deemed biocompatible towards HeLa and CHO cells at 
concentrations below 100 µg mL-1, concentrations above 200 µg 
mL-1 cause cellular damage.[81] Our experiments are carried out 
by using final concentrations (10 µg mL-1) that are 200 times lower 
that one resulting in cellular degradation. Furthermore, over the 
course of four hours, the morphology of FEK-4 is largely 
unchanged. Such results and considerations seem to suggest 
that the concentration of the silica NPs used during our 
experiments are unlikely to produce cellular damage. Therefore, 
the internalization should not be considered as a result of cellular 
degradation. 
The observation that these nanoparticles are fully dispersible 
and kinetically stable in aqueous media, yet do not appear to 
penetrate the cellular membrane over short timescale in such a 
typical (healthy) cell line is promising for their use in future 
bioimaging applications of gallium-68. They are potentially 
valuable as imaging probes where it is desirable that nanoimaging 
agents do not enter healthy (non-diseased) cells in an 
uncontrolled manner. They are stable over lifetimes compatible 
with the short half-lives of gallium-68 and with optical imaging 
experiments.  
By encapsulating the Cd0.1Zn0.9Se nanocrystals in a thin silica 
matrix along with magnetic nanoparticles, we achieved a water 
dispersible system that retains the optical features of the free QDs 
as well as the magnetic properties of the iron oxide core. To the 
best of our knowledge, such NPs represent the first example of 
coated QDs which emit in two different and distinct regions of the 
spectrum. These fluorescent features potentially make such 
inorganic NPs a unique and versatile device for biological 
applications. Therefore, we explored the possibility that this may 
render these core-shell materials as a tool for in vitro fluorescence 
imaging or ratiometric uses in environmental sensing.[30] 
 
Functionalization of the MNPs surface with a known hypoxia 
tracer. 
 The presence of a silica layer provides an opportunity for 
further functionalization being easily decorated with ligands such 
as biomolecules or drugs. Lu et al. reported that the monoclonal 
antibody to the  unit of human chorionic gonadotrophin (anti--
hCG) is absorbed on the silica surface, adopting a “flat-on 
conformation at the interface.[82] Moreover, silica is biocompatible 
and protects the iron oxide from degradation or aggregation, while  
eliminating the toxicity of the core, as proven by our MTT assays 
(Figure 6).[1],[83]  
To illustrate one possibility for exploiting this potential 
functionalization, we synthesized a metal-ligand complex that has 
potential selectivity for hypoxic tissue in vivo and in vitro when is 
labelled with some radioisotopes. Functionalization 
methodologies of zinc bis(thiosemicarbazonato) complexes were 
reported by Dilworth et al.[84] who investigated the reaction of 
bis(thiosemicarbazonato) complexes with α-β-D-glucose as proof 
of principle of bioconjugation processes. To demonstrate that the 
outer surface of our Fe3O4@SiO2 (A) NPs can be functionalized 
via a condensation reaction, we investigated the reaction between 
Fe3O4@SiO2 (A) and [ATSM]/A metal complexes with a pendant 
amino group. For example, the amino group of Zn[ATSM]/A can 
react to form Si-N bonds at the surface. (Figure 1). Fe3O4@SiO2 
(A) NPs and Zn[ATSM]/A were heated under reflux overnight in 
methanol. Single-photon confocal microscopy images of PC-3 
cells incubated with Fe3O4@SiO2@Zn[ATSM]/A (D) NPs are 
shown in Figure S51-S52. While a homogeneous distribution of 
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the particles is seen in the blue and green channels with 405 nm 
excitation, aggregates of the fluorescent probes are particularly  
Figure 6. IC50 in PC-3 cells after 48 hours treatment with 
Fe3O4@SiO2@Zn[ATSM]/A (D), Cd0.1Zn0.9Se and 
Fe3O4/Cd0.1Zn0.9Se@SiO2 (C) nanoparticles. (D) (IC50 = 6.77·10-5 ± 
1.60·10-5 mg/mL; Cd0.1Zn0.9Se IC50 = 5.07·10-5 ± 9.40·10-6 mg/mL; (C) 
IC50 = 6.76·10-4 ± 1.25·10-5 mg/mL; Zn[ATSM]/A = 5.96·10-3 ± 1.57·10-
3 mg/mL. 
visible in the green and red channels using 488 nm and 561 
nm excitation. Such aggregates might be caused by a dynamic 
interaction between the particles and endosomes/lysosomes, as 
recently discovered by Gu and collaborators.[62] 
 
Cellular viability tests 
Standard MTT assays were performed in order to 
investigate the effect of silica encapsulation and surface 
functionalization on the cellular viability compared with pristine 
QDs (Figure 6). Fe3O4/Cd0.1Zn0.9Se@SiO2 (C) NPs have similar 
IC50 to cisplatin which is used to treat a variety of tumours (IC50 = 
7.20·10-4 mg/mL measured over 72h).[85] The IC50 had lower (up 
to ten times) cytotoxicity (IC50 = 6.76·10-4) than the Cd0.1Zn0.9Se 
(IC50 = 5.07·10-5) nanocrystals (Figure 8). The functionalization of 
the silica shell lowers IC50 (6.77·10-5 mg/mL) from that of the 
unmodified surface. This might be caused by loss of metal cations. 
However, the results demonstrate that encapsulation of 
Cd0.1Zn0.9Se and F3O4 NPs within a silica shell improves the in 
vitro biocompatibility of the QDs used in this work. 
 
Radiolabelling of nanocomposites using PET isotopes 64Cu 
and 68Ga 
The ability to functionalise the surface of the nanocomposite 
particles offers the possibility of supramolecular trapping or 
encapsulation of a radionuclide under the limited or no-carrier-
added radiochemistry conditions. Various approaches have been 
used to devise radiolabelling protocols but this remains a 
synthetic challenge since the processes involved are under subtle 
kinetic control.  
In this work, we demonstrate that it is possible to radiolabel the 
magnetic and fluorescent nanocomposites with both 68Ga and 
64Cu radioisotopes via the general methods developed, in most 
cases via chelator-free methods. 68Ga and 64Cu offer different 
advantages. They both undergo β+ decay, which allows in vivo 
PET imaging. 64Cu also has a characteristic low energy β− 
emission which is effective for radiotherapy of tumour lesions with 
minimal effect on surrounding tissues.[86],[87] Regarding their 
production, 64Cu is available through a cyclotron, whilst 68Ga can 
be obtained from a commercial generator.[88],[89]  
 To address radioactivity incorporation challenges, four 
radiolabelling methods were devised as summarised in Figure 7. 
Method 1 involves non-covalent adsorption of [68Ga]GaCl3 onto 
the silica surface of Fe3O4@SiO2 (A) and 
Fe3O4/Cd0.1Zn0.9Se@SiO2 (C). A and C NPs were dispersed in 
DMSO and heated to 95 °C for 40 min with the pH adjusted to 4.5. 
For all radiolabelling experiments, a sodium acetate buffer was 
used as an adjuvant to improve the encapsulation yield and to 
adjust the pH. The resulting magnetic nanomaterials were 
separated using a permanent magnet and centrifuged. The 
particles were then washed with methanol and water.  
The formation of a second silica shell around these 
nanocomposites which trapped the radionuclides was explored 
using method 2 with [68Ga]GaCl3 and [64Cu]Cu(OAc)2. By 
following method 2, [68Ga]GaCl3 was added to a DMSO 
suspension of Fe3O4@SiO2 (A) or Fe3O4/Cd0.1Zn0.9Se@SiO2 (C) 
NPs with TEOS and cyclohexane. The resulting mixture was 
heated to 95 °C for 68 min. The added TEOS generated a second 
layer of silica trapping the radioisotope. The resulting 
radiochemical incorporation was found to be 70%, and due to the 
short half-life of 68Ga, the reaction conditions could not be further 
optimised. However, the longer half-life of 64Cu allowed us to 
validate the radiolabelling protocol in water at room temperature 
(see ESI). [64Cu]Cu(OAc)2 was incorporated as the radioactive 
material following methods 2 and 3. In order to optimize the 
radiolabelling protocols, six different, parallel assembly routes 
were used (details are given in ESI). Different amounts of 64Cu 
radiotracer were added during the coating process at pH 8. 
The longer half-life of [64Cu]Cu(OAc)2 allowed for a 7 h, one-pot 
encapsulation protocol (method 3) using Fe3O4, [64Cu]Cu(OAc)2 
and TEOS. These three methods give a general approach which 
is also valid for other metaloisotopes in aqueous media. The 
methods can be adjusted to suit the half-life of the particular 
radionuclide, such as 89Zr (t1/2 = 78.4 h). While methods 1, 2 and 
3 are based on the self-assembly of the precursors within a silica 
network, we also investigated in method 4 (details in ESI) the 
possibility of radiolabelling Fe3O4@SiO2@Zn[ATSM]/A (D) NPs 
via a transmetalation reaction involving Zn and the relevant 
radionuclide (e.g. 68Ga).        
Taking into account the half-life of both radioisotopes, the 
decay-corrected radiolabel incorporations were estimated. Over 
99.9% incorporation was achieved from the non-covalent 
adsorption of [68Ga]GaCl3 onto the silica surface. A value of 94% 
was achieved using [64Cu]Cu(OAc)2 in a one-pot protocol 
(method 3), and 84% was obtained by following a step-wise 
reaction with the same radioisotope (method 2). Using 
[68Ga]GaCl3 in method 2 led to 70% incorporation of the  
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Figure 7. Synthesis and encapsulation methods for radiolabelled and non-radiolabelled MNPs imaging probes. 
 
radionuclide. The method using transmetalation of 
Fe3O4@SiO2@Zn[ATSM]/A (D) NPs (method 4) gave 65% with 
[64Cu]Cu(OAc)2 although with 68Ga the radiochemical 
incorporation increased to > 99.9%. However, this remarkable 
value may well be explained by a surface adsorption process 
which facilitates the radiochemical incorporation of [68Ga]GaCl3 as 
in method 1. The maximum efficiency was reached when 68Ga 
was injected into a suspension of silica coated NPs, following 
method 1. As a control, free Zn[ATSM]/A in ethanol was 
subjected to the same experimental conditions used for 
radiolabelling  
Fe3O4@SiO2@Zn[ATSM]/A (D) NPs. According to previous work 
by Pascu and co-workers,[49] the labelling of Zn[ATSM] complexes 
with 68Ga was unsuccessful. Therefore, we conclude that the 
covalent bond between the ATSM ligand and the silica surface 
plays a crucial role in the 68Ga radiolabelling process.   
 Virtually no loss of the radioactivity of the 64Cu radiolabelled 
nanoparticles dispersed in water was noted 7 h after 
encapsulation, showing that the encapsulated material does not 
leak out. The loading mechanism of 64Cu acetate (a well-known 
monohydrate complex which adopts the paddle-wheel 
structure[90] of ca. 9 Å diameter) is likely based on solvophobic 
interactions reinforced by H-bonds within the [SiO2]n matrix 
formed in the microemulsion environment, efficiently trapping the 
radionuclide and resulting in leak-free radioactive nanoparticles 
which are stable in aqueous media for weeks. After decay (3  
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Table 1. Summary of optimised radiolabelling methods and associated radio-incorporation (%) with respect to precursors. 
Procedure Compound Radioisotope Yield (%) 
Method 1 
(Non-covalent adsorption) 
(G); (E) [68Ga]GaCl3 >99.9 ± 0.1 
Method 2 
(Encapsulation of the radioisotope within a 
second layer of silica) 
(L) [64Cu]Cu(OAc)2 84 ± 0.5 
Method 2 
(Encapsulation of the radioisotope within a 
second layer of silica) 
(J) [68Ga]GaCl3 70 ± 0.5 
Method 3 
(One pot encapsulation reaction) 
(F) [64Cu]Cu(OAc)2 94 ± 0.5 
Method 4 
(Transmetallation reaction with Zn[ATSM]/A) 
(H) [64Cu]Cu(OAc)2 65 ± 0.5 
Method 4 
(Transmetallation reaction with Zn[ATSM]/A) 
(I) [68Ga]GaCl3 >99.9 ± 0.1 
 
Figure 8. Optimised radio-incorporation results emerging for each 
labelling method reported, using aqueous [64Cu]Cu(OAc)2 and [68Ga]GaCl3 
precursors (see ESI). 
weeks), TEM micrographs of the 64Cu radiolabelled MNPs were 
compared with freshly prepared, non-radioactive nanoparticles. 
When 64Cu solution was added after the pre-coating period 
(method 2), the shape of the core-shell NPs was maintained 
(ESI) and no significant changes in shape and size or in 
aggregation were observed. These results demonstrate the 
possibility of synthesizing a trimodal imaging agent which is highly 
stable with respect to radioactive agent loss. The results with the 
highest labelling incorporation percentage following each different 
radiolabelling method are reported in Table 1 and Figure 8. 
Conclusions 
In conclusion, magnetic iron oxide nanoparticles incorporating 
Fe3O4 cores and Cd0.1Zn0.9Se quantum dots were simultaneously 
encapsulated within ca. 10 nm silica shell, giving rise to water-
dispersible, biocompatible and luminescent NPs with dimensions, 
ranging between 30-50 nm, which retained the magnetic 
properties. These were found to retain some of the emissive 
characteristics of the encapsulated QDs while still exhibiting 
magnetic properties due to the Fe3O4 core. Cellular interactions 
over a timescale of 30 min – 6 h and incubation at 37 °C were 
visualized by epi- and confocal fluorescence microscopies. 
Surface modification allowed incorporation of two radiolabelled, 
Gallium-68 and Copper-64. The materials appear to be non-toxic 
and constitute a promising, safe-to-handle and benign hybrid 
nanoparticles of potential utility as tri-modal medical imaging 
probes that allow a simultaneous PET, MRI and fluorescence 
imaging. However, the optimization of the formulation for an 
effective and simultaneous use of these nanocomposites for 
multimodal imaging remains a challenge. While this study has 
focused mainly on new fine-tuning encapsulation methods, 
preliminary experiments suggest that this approach can be 
extended to biologically or medically relevant nanoscaffolds and 
offers the potential for measuring the speciation of such systems 
in living cells. In future we envisage to extend this work towards 
other relevant PET radionuclides such as fluorine-18.[91] 
Experimental section  
All manipulations were carried out by using standard Schlenk 
glassware and glove box techniques. All solvents were used as 
purchased and degassed by bubbling nitrogen for 30 min. 
Trioctylphosphine oxide (TOPO, 99%), trioctylphosphine (TOP, 
90 %), octadecylamine (ODA, 90%), stearic acid (95%), 
diethylzinc (ZnEt2, 1.0 M solution in heptane), and Se powder 
(99.999%) were purchased from Aldrich. Cadmium stearate was 
purchased from Greyhound Chromatography. Zn[ATSM]/A was 
synthesised in accordance with a previously reported 
procedure.[84] Further details of the experimental synthetic 
procedures used to synthesise compounds and materials 
mentioned in this work can be found in the supporting information. 
TEM micrographs, IR spectra, DLS, UV-vis, 2D fluorescence 
spectra, as well as information regarding cell culture, MTT assays, 
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epi-fluorescence and confocal microscopy imaging are also given 
in the ESI. 
 
Synthesis of Fe3O4nanoparticles.  
10 mL of 1 M FeCl3 were mixed with 2.5 mL of 2 M FeCl2 dissolved 
in 2 M HCl. Both solutions were freshly prepared with 
deoxygenated water before use. Immediately after being mixed 
under nitrogen, the solution containing iron chlorides was added 
to 125 mL of potassium hydroxide solution (0.7 M) under vigorous 
mechanical stirring and under a nitrogen atmosphere. After 30 
min, the black precipitate formed was separated magnetically 
using a standard permanent magnet and washed with water 
(3×250 mL). Finally, oleic acid (5 mmol) was dissolved in 5 mL of 
acetone and was dropwise added. 
 
Coating of MNPs with a silica shell using microemulsion method 
44.60 g of polyoxyethylene(5)isooctylphenyl ether (IGEPAL CA-
520) was dispersed in 700 mL of cyclohexane. Then, 200 mg of 
Fe3O4 nanoparticles dispersed in cyclohexane (20 mg·mL-1) was 
added. The mixture was stirred until it became transparent. After 
this step, 9.44 mL of ammonium hydroxide (29% aqueous 
solution) was added to form a reverse microemulsion. Finally, 
7.70 mL of tetraethylorthosilicate (TEOS) was added. The 
solution was gently stirred for 16 h. The nanocomposite was 
precipitated with methanol and separated by magnetic 
decantation. 
 
Synthesis of Cd0.1Zn0.9Se QDs 
Stock solutions for Se and ZnEt2 were prepared in a glovebox 
under argon atmosphere. Cadmium stearate (0.2044 g, 0.3 mmol), 
stearic acid (0.1707 g, 0.6 mmol), TOPO (5.0 g), and ODA (5.0 g) 
were added to a flask, and the mixture was heated, under stirring, 
to 330 °C under a flow of argon until a clear solution formed. At 
this temperature, a solution containing 0.1184 g of Se (1.5 mmol) 
dissolved in TOP was injected into the reaction flask and the 
temperature was set to 290 °C. After 5-10 min. under stirring, the 
heating was removed to stop the reaction and allow the flask to 
cool to room temperature. After 1h, the mixture of CdSe and 
organic ligands was heated up to 300 °C again. An aliquot (3 mL) 
of the as-prepared crude CdSe reaction mixture, containing 0.1 
mmol of CdSe, were transferred to a three-neck Schlenk flask and 
heated at 300 °C. At this temperature, 0.450 mL of ZnEt2 (TOP 
solution, 0.2 M) and 0.450 mL of Se (TOP solution, 0.2 M) were 
injected. T the reaction mixture was heated for 6 min. Once the 
mixture reached room temperature, 9 mL of chloroform was 
added under stirring. Quantum dots were precipitated in a mixture 
1:1 of methanol/acetone and isolated by centrifugation and 
decantation. A mixture of methanol/acetone (5×25 mL) was used 
to wash the QDs from the excess of organic ligands. Finally, 
Cd0.1Zn0.9Se nanocrystals were dispersed in 9 mL of n-hexane 
and characterized by optical spectroscopy. 
 
Synthesis of Fe3O4/Cd0.1Zn0.9Se@SiO2 (C) NPs 
In a typical experiment, 0.223 g of 
polyoxyethylene(5)isooctylphenyl ether was dispersed in 3.5 mL 
of cyclohexane. Then, 1.0 mg of Fe3O4 dispersed in cyclohexane 
(20 mg/mL) was added, followed by 50 µl of QD (1.50 mg/mL). 
The mixture was stirred until it became transparent. After this step, 
45 µl of ammonium hydroxide (29% aqueous solution) was added 
to form a reverse microemulsion. Finally, 39 µL of TEOS was 
added. The solution was gently stirred for 16 hours. The 
nanocomposite was precipitated with methanol and separated by 
magnetic decantation. 
 
Synthesis of Fe3O4@SiO2@Zn[ATSM]/A (D) 
30 mg of Fe3O4@SiO2 nanoparticles were dispersed in 100 ml of 
methanol, followed by 30 mg of Zn[ATSM]/A. The mixture was 
mechanically stirred and heated to 80 oC under reflux. After 16 h, 
the nanocomposite was separated by magnetic decantation and 
washed with further methanol (3 x25 mL). 
 
Synthesis of 68Ga radiolabelled MNPs 
[68Ga]GaCl3 was produced and eluted through a 68Ge/68Ga 
generator in a saline/HCl (0.02 M) solution. Method 1. 50 μL of 
MNPs (A and C) (1 mg/mL DMSO stock solution) were dispersed 
in 0.4 ml of ethanol. 100 μL of [68Ga]GaCl3 stock solution (37 MBq 
in 500 μL) were added to the suspension, and the pH was 
adjusted to 5 by adding 1 mL of sodium acetate buffer solution 
(pH 4.5). The reaction was carried out for 40 min at 90 °C (using 
the vortex every 10 minutes). Method 2. 0.223 g of 
polyoxyethylene (5) isooctylphenyl ether (IGEPAL CA-520) was 
dispersed in 3.5 mL of cyclohexane. Then, 30 μL of MNPs (A and 
C) (dispersed in DMSO (1 mg/mL)) were added and the mixture 
was stirred in a vortex. Next, 45 μL of ammonium hydroxide (29 % 
aqueous solution) was added to form a reverse microemulsion, 
followed by 15 μL of TEOS. Finally, 50 μL [68Ga]GaCl3 stock 
solution was added to the reaction vial, and the solution was 
heated to 90 °C and reacted for 68 min (sonicated every 10 min). 
Method 4. 50 μL of Fe3O4@SiO2@Zn[ATSM]/A (D) NPs (2 mg/mL 
DMSO stock solution) were dispersed in 0.4 mL of ethanol. 100 
μL of [68Ga]GaCl3 stock solution (37 MBq in 500 μL) were added 
to the suspension, and the pH was adjusted to 5 by adding 1 mL 
of sodium acetate buffer solution (pH 4.5). The reaction was 
carried out for 40 minutes at 90 °C (using the vortex every 10 
minutes). For all the experiments, the nanocomposite was 
transferred to centrifuging vials and washed with 0.5 mL of 
methanol and water (3 x 0.5 mL) and separated by magnetic 
decantation or using centrifugal filters. Each experiment was 
carried out three times. 
 
Synthesis of 64Cu radiolabelled MNPs 
[64Cu]CuCl2 was produced on a medical cyclotron using the 
64Ni(p,n)64Cu nuclear reaction and purified using a using an ion-
exchange column. A stock solution of [64Cu]Cu(OAc)2 was 
prepared at pH 8.4, using 10 mM NaOAc solutions. Method 2 and 
3. 0.223 g of polyoxyethylene (5) isooctylphenyl ether was 
dispersed in 3.5 mL of cyclohexane. Then, 1.0 mg of Fe3O4 (or A) 
dispersed in cyclohexane (20 mg/mL) was added. The mixture 
was stirred until it became transparent. After this step, 45 μL of 
ammonium hydroxide (29 % aqueous solution) was added to form 
a reverse microemulsion, followed by 15 μL of TEOS. The 
reaction was carried out for 2 hours and subsequently, 25 μL of 
[64Cu]Cu(OAc)2 (aq) (from a 100 MBq stock solution) was added 
together with an additional 24 μL of TEOS. The solution was 
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gently stirred for 5 hours. Method 4. 50 μL of D (1 mg/mL DMSO 
stock solution) were dispersed in 0.4 mL of H2O. 0.2 mL of 
[64Cu]Cu(OAc)2 (aq) solution were added to the suspension. The 
reaction was carried out for 40 minutes at 90 °C (using the vortex 
every 10 min). For all the experiments, the nanocomposite was 
precipitated with methanol (3 x 0.5 mL) and separated by 
magnetic decantation. Each experiment was carried out three 
times. 
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Scalable and post-synthetic surface 
modification protocols to attach 
64Cu and 68Ga radioisotopes to 
fluorogenic composite materials are 
reported. Covalent and non-
covalent synthetic procedures are 
designed to obtain versatile, 
adaptable magnetic and 
luminescent biocompatible core-
shell nanoceramics which were 
extensivelly characterised, e.g. by 
DLS, TEM, EDX. The potential of 
such radio-nanocomposites to act as 
cellular bioimaging agents are 
investigated via confocal 
fluorescence microscopy, UV-Vis, 
single and multi-photon FLIM, and 
TCSPC and validated by MTT 
assays. 
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